We studied data generated during a previously reported phase 1/2 clinical trial26,27, which assessed the safety and efficacy of the addition of a CCR5 antagonist (maraviroc) to standard GVHD prophylaxis. This evidence concerns the gene CCR5 and graft versus host disease.